Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years

García-Velasco, Adelaida; Zacarías-Pons, Lluís; Teixidor, Helena; Valeros, Marc; Liñan, Raquel; Carmona-García, Maria Carmen; Puigdemont, Montse; Carbajal, Walter; Guardeño, R.; Malats, Núria; Duell, Eric J.; Marcos‐Gragera, Rafael

doi:10.3390/ijerph17249538

Cited by 3 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Smith [12], the breast cancer surveillance guidelines are discussed. We observe that the Kaplan-Meier method is universal and can be applied not only to the study of breast cancer treatment but also to other cancers to compare the survival of different groups of patients after diagnosis, see for instance [13][14][15][16][17][18][19][20][21][22][23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Actuarial Analysis of Survival among Breast Cancer Patients in Lithuania

et al. 2021

View full text Add to dashboard Cite

Breast cancer is the most common cause of mortality due to cancer for women both in Lithuania and worldwide. Chances of survival after diagnosis differ significantly depending on the stage of disease at the time of diagnosis. Extended term periods are required to estimate survival of, e.g., 15–20 years. Moreover, since mortality of the average population changes with time, estimates of survival of cancer patients derived after a long period of observation can become outdated and can be no longer used to estimate survival of patients who were diagnosed later. Therefore, it can be useful to construct analytic functions that describe survival probabilities. Shorter periods of observation can be enough for such construction. We used the data collected by the Lithuanian Cancer Registry for our analysis. We estimated the chances of survival for up to 5 years after patients were diagnosed with breast cancer in Lithuania. Then we found analytic survival functions which best fit the observed data. At the end of this paper, we provided some examples for applications and directions for further research. We used mainly the Kaplan–Meier method for our study.

show abstract

Section: Introductionmentioning

confidence: 99%

Actuarial Analysis of Survival among Breast Cancer Patients in Lithuania

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The high mortality could be explained because approximately 80% to 85% of patients were diagnosed at advanced stages, when surgical treatment is contraindicated [2]. Thus, the five-year survival might have been less than 7% in all patients in Europe during the period 2000-2007 [2,3], and might have reached 20% in cases where the tumor could be resected [4]. In Spain, there were an estimated 8218 new cases of pancreatic cancer in 2020, and this figure is expected to increase by 45% by 2040 [1].…”

Section: Introductionmentioning

confidence: 99%

“…Over 80% of pancreatic carcinomas could be caused by sporadic mutations, while 10% to 15% could be due to germline mutations [2,[5][6][7][8]. In general, pancreatic ductal adenocarcinoma is the most frequent type (≥80%), followed by neuroendocrine tumors of the pancreas [2,3,8]. These tumors are often diagnosed in older people [2,3,9], with approximately 70% of new cases occurring in patients over 65 years of age in Europe [1].…”

Section: Introductionmentioning

confidence: 99%

“…In general, pancreatic ductal adenocarcinoma is the most frequent type (≥80%), followed by neuroendocrine tumors of the pancreas [2,3,8]. These tumors are often diagnosed in older people [2,3,9], with approximately 70% of new cases occurring in patients over 65 years of age in Europe [1]. Age is therefore an important risk factor for the development of this tumor, and it is also a consideration in decisions on the best therapeutic approach to follow [7,[10][11][12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Management, Survival, and Costs of Pancreatic Cancer: Population-Based Observational Study in Catalonia

Guarga

Paco²,

Manchon-Walsh

et al. 2023

IJERPH

View full text Add to dashboard Cite

Aim: Few published studies comprehensively describe the characteristics of patients with pancreatic cancer and their treatment in clinical practice. This study aimed to describe the current clinical practice for treating pancreatic cancer in Catalonia, along with the associated survival and treatment costs. Methods: A retrospective observational cohort study in patients diagnosed with pancreatic cancer from 2014 to 2018, using data from the healthcare records of the Public Health System of Catalonia, was conducted. Treatment patterns and costs were described by age groups from 2014 to 2018, with survival reported until December 2021. Results: The proportion of patients receiving surgery with curative intent was low, especially in older patients (23% of patients <60 years and 9% of patients ≥80 years). The percentage of patients treated with drugs for unresectable disease also decreased with age (45% of patients <60 years and 8% of patients ≥80 years). Although age was associated with significant differences in survival after curative surgery, no differences attributable to age were observed in patients who received pharmacological treatment for unresectable disease. In patients under 60 years of age, the mean cost of the first year of treatment was EUR 17,730 (standard deviation [SD] 5754) in those receiving surgery and EUR 5398 (SD 9581) in those on pharmacological treatment for unresectable disease. In patients over 80, the mean costs were EUR 15,339 (SD 2634) and EUR 1845 (SD 3413), respectively. Conclusions: Half of the patients diagnosed with pancreatic cancer did not receive specific treatment. Surgery with curative intent was associated with longer survival, but only 18% of (mostly younger) patients received this treatment. Chemotherapy was also used less frequently in patients of advanced age, though survival in treated patients was comparable across all age groups, so careful oncogeriatric assessment is advisable to ensure the most appropriate indication for eligibility in older patients. In general, earlier diagnosis and more effective pharmacological treatments are necessary to treat frail patients with high comorbidity, a common profile in older patients.

show abstract

“…Previous studies examining the distribution of morphological subtypes have been limited to one country [5,8]. Additionally, studies examining survival have been limited to either one morphological sub-type or to one country or region, if including more than one morphological sub-type [5,[9][10][11]. Using data from all 295 population-based registries participating in CONCORD-3 that submitted data on pancreatic cancer, we examined whether the distribution of morphological sub-types could help explain international variations in survival.…”

Section: Introductionmentioning

confidence: 99%